Splice Bio: Funding, Investors & Team (Sep 2026)
SpliceBio develops genetic medicines through its innovative Protein Splicing platform, focusing on gene therapies for genetic diseases. The company aims to address conditions caused by mutations in large genes, utilizing proprietary technologies to create novel treatment options. SpliceBio's pipeline includes programs targeting specific genetic disorders, such as Stargardt Disease. By leveraging its expertise in protein splicing, the company seeks to advance the field of gene therapy and improve patient outcomes. Through ongoing research and development, SpliceBio contributes to the understanding and treatment of complex genetic conditions.
Splice Bio has raised $135M across 1 funding round on record, the most recent a Series B of $135M announced in Jun 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Splice Bio Company Profile and Key Stats
Latest funding round on record: Jun 2025.
Splice Bio Funding Rounds
Splice Bio Founders and Leadership Team
No contact details are on record for this team yet.
Splice Bio Funding Compared to Other Biotechnology Startups
Splice Bio's latest round of $135M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Splice Bio in Biotechnology and Barcelona
Companies Similar to Splice Bio
iPremom is a healthcare technology company that develops molecular diagnostic solutions for the early…
Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological…
Ona Therapeutics is a biotech company that specializes in the discovery and development of therapeutic…
IMPETUX develops and markets patented technology to characterise the mechanical properties of living tissues…
Molecular Gate refer to an innovative class of small-molecule drugs developed by Gate Bioscience. These drugs…
Modern medicine fails because it studies life in static environments. 60Nd revolutionizes the field with…
Devicare designs point-of-care medical devices that monitor, diagnose and treat chronic diseases. The…
Universal Diagnostics S.A. (UDX) is a company in Spain that specializes in in-vitro diagnostics. Their focus…
Phyture Biotech originated as a spin-off of the Faculty of Pharmacy at the University of Barcelona, founded…
Polimerbio offers sanitary product design and development based on biocompatible polymers, particularly…
Overture Life is a biotechnology company that specializes in developing automated technologies for assisted…
In order to cure diseases with unmet medical requirements, ARTHEx Biotech, a biotech business that was spun…
Splice Bio Funding FAQs
What does Splice Bio do?
SpliceBio develops genetic medicines through its innovative Protein Splicing platform, focusing on gene therapies for genetic diseases. The company aims to address conditions caused by mutations in large genes, utilizing proprietary technologies to create novel treatment options. SpliceBio's pipeline includes programs targeting specific genetic disorders, such as Stargardt Disease. By leveraging its expertise in protein splicing, the company seeks to advance the field of gene therapy and improve patient outcomes. Through ongoing research and development, SpliceBio contributes to the understanding and treatment of complex genetic conditions.
How much funding has Splice Bio raised?
Splice Bio has raised $135M across 1 round on record. The most recent is a Series B of $135M announced in Jun 2025.
When did Splice Bio last raise funding?
Splice Bio's most recent funding round on record is a Series B of $135M, announced in Jun 2025.
Who founded Splice Bio?
FundedIQ lists Miquel Vila Perello (Founder) at Splice Bio.
Where is Splice Bio headquartered?
Splice Bio is based in Barcelona, Catalonia, Spain.
How many employees does Splice Bio have?
Splice Bio is in the 11-50 employee band.
How does Splice Bio's funding compare to other Biotechnology startups?
Splice Bio's latest round of $135M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Splice Bio Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Splice Bio is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.